Ignite Creation Date:
2024-05-05 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00348881
Status:
COMPLETED
Last Update Posted:
2013-10-22
First Post:
2006-07-05
Brief Title:
Study Comparing a DTaP-HB-PRPT Combined Vaccine With Tritanrix HepBHib Concomitantly With OPV in Healthy Infants
Sponsor:
Sanofi Pasteur a Sanofi Company
Organization:
Sanofi
Study Overview
Official Title:
Large Scale Safety and Immunogenicity Study of a DTaP-Hep B-PRP-T Combined Vaccine Compared to Tritanrix HepBHib Both Given Concomitantly With OPV at 6 10 and 14 Weeks of Age in Healthy Filipino Infants
Status:
COMPLETED
Status Verified Date:
2013-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study to compare the safety and immune response of a pentavalent DTaP-HB-PRPT combined vaccine with Tritanrix-HepBHib when both are given concomitantly with OPV at 6 10 and 14 weeks of age
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None